Kokua Pharma

Kokua Pharma is a clinical-stage biotechnology company focused on developing innovative topical treatments for neuropathic pain conditions. The company's lead candidate, KOK-101, is a proprietary topical formulation of gabapentin designed to provide localized relief for post-herpetic neuralgia while minimizing systemic side effects. By leveraging specialized drug delivery technology, Kokua Pharma aims to improve the safety and efficacy profile of established analgesic agents. The company targets high-unmet-need areas within the pain management sector, specifically for patients who cannot tolerate the central nervous system side effects of oral gabapentinoids. Kokua Pharma is headquartered in San Diego, California, and continues to advance its clinical pipeline through mid-stage trials.